Overview
ASCLETIS-B (1672)
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland...
- Open
- 4.500
- High
- 4.630
- Low
- 4.215
- Prev. Close
- 4.695
- Volume
- 1.55M
- Turnover
- 6.71M
- Avg Price
- 4.338
- Bid/Ask Ratio
- 45.45%
- Amplitude
- 8.84%
- 52wk High
- 19.860
- Volume Ratio
- 0.43
- Turnover Ratio
- 0.15%
- 52wk Low
- 4.115
- HK Mkt Cap
- 4.50B
- Market CapHKD
- 4.50B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.647
- EPSDynamic
- -0.700
- EPSStatic
- --
- BVPS
- 2.48
- P/B
- 1.72
- HK Shares
- 1.05B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.05B
- Min lot size
- 1,000
- Currency
- HKD
ASCLETIS-B Analyst Rating
View moreForecast & Rating
Sep 2, 2026- Strong buy33.33%
- Buy33.33%
- Hold33.33%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 1
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Ascletis Pharma fell 9.1% to HK$4.270 on 16 November from the prior close of HK$4.695 on HK$6.54 million turnover, tracing a one-way decline: it opened at HK$4.695 in the morning session, slid to HK$4.410 by the 11:59 break and touched an intraday low of HK$4.220 at 13:59 before a small close-of-day recovery. News flow centred on an FDA IND filing for ASC30_39 in obesity, several buyback-for-cancellation filings and a grant of 1.8 million employee options, while early readouts — ASC37's half-life six times longer than retatrutide and a 1.7% HbA1c cut at 12 weeks for the oral GLP-1 — have yet to generate revenue; Q2 2026 EPS was -HK$0.1776 and the net loss of HK$184.6 million widened 283% year on year. The price sits just 3.8% above its 52-week low of HK$4.115, is down 62.9% year to date, 78.5% below the April 19 high of HK$19.86, and under the MA20 of HK$5.023 and MA60 of HK$7.553, though repeated buybacks and a 1.72x PB against a negative PE indicate pricing still tracks pipeline expectations rather than current earnings.
- Nov, 13
Ascletis Pharma reversed an early slide to close at HK$4.85, up 0.21% from HK$4.84, after touching 4.64 at 09:31 BJ and 4.58 at 14:50 BJ before recovering to 4.85 near the 4.86 intraday high; volume of 2.331 million shares (HK$10.96 million) and a thin 0.22% turnover rate point to sentiment repair rather than fresh capital. Pipeline headlines clustered: an FDA IND filing for ASC30_39 in obesity, ASC37's half-life reported six-fold longer than retatrutide, and oral GLP-1 cutting HbA1c 1.7 percentage points versus placebo at 12 weeks, alongside repeated buyback-for-cancellation disclosures. Fundamentals still lag, with Q2 EPS of -HK$0.1776 and a net loss of HK$184.6 million that widened 283% year on year, ROE at -28.15%, while the price sits below MA20 of 5.11 and MA60 of 7.65, down 57.9% year to date, 75.6% under the 52-week high of 19.86 and just 17.9% above the November 3 low of 4.115, though a PE of -7.49 shows earnings support is still absent.
- Nov, 12
Ascletis opened at 4.775, dipped to 4.675 at 09:43 BJ, then reversed higher after the company filed an FDA IND application for its ASC30/ASC39 obesity programme, peaking at 5.060 at 13:15 BJ before paring gains to close at 4.950 HKD, up 3.66% on 2.8 million shares worth 13.72 million HKD; repeated buybacks for cancellation also eased selling pressure after the stock touched a 52-week low of 4.115 on 3 November. Pipeline disclosures added support: ASC37 showed a half-life six times longer than retatrutide, and the oral GLP-1 cut HbA1c by 1.7% versus placebo at 12 weeks. Fundamentals remain weak, with a Q2 2026 net loss of 184.6 million HKD widening 283% year on year, EPS of -0.1776 HKD, ROE of -28.15% and no reported revenue, leaving PE negative and PB at 1.99. At 4.950 the stock sits below MA20 of 5.159 and MA60 of 7.739, down 57.03% year to date, 75.08% below its 52-week high of 19.86 and only 20.29% above the low. Though the buyback and IND filing still await clinical validation.
- Nov, 9
Ascletis-B rose 7.3% to HK$4.88, extending a rebound from the 52-week low of HK$4.115 set on 3 November, as buybacks and ObesityWeek 2026 disclosures reinforced each other: the company repurchased 200,000 shares for HK$960,600 on 5 November and 100,000 shares for HK$459,700 on 6 November, while data showed ASC37's half-life roughly six times longer than retatrutide and the oral GIPR agonist ASC48 was presented at the same conference. Intraday the stock spiked to HK$5.045 at 09:32 in the morning session, sank to HK$4.655 at 15:46 in the afternoon and closed at HK$4.88 on 2.135 million shares worth HK$10.28 million, a thin 0.20% turnover rate. Fundamentals remain weak: the Q2 2026 net loss was HK$184.6 million, 283% wider year on year, with EPS of -HK$0.1776; the shares sit below the MA20 of HK$5.407 and MA60 of HK$8.014, down 57.64% year to date and 75.43% below the 19 April peak of HK$19.86. Whether the buyback pace near the 52-week low persists is still to be seen.
- Nov, 6
Ascletis fell 7.8% to HK$4.515 after opening at HK$4.710, briefly rising to HK$4.735 and later sliding to HK$4.505, as the Hong Kong innovative-drug complex weakened again; GENSCRIPT BIO dropped over 15%, KEYMED BIO-B nearly 5%, and the Life Sciences Index fell for a fourth session. The company bought back 200,000 shares for HK$960,600 on November 5, which did not arrest the decline. Q2 2026 net loss was HK$184.6 million, 283% wider year on year, with EPS at -HK$0.1776. The stock sits 77.3% below its 52-week high of HK$19.86, down 60.8% YTD, and below MA20 of HK$5.52 and MA60 of HK$8.115. Still, ASC30 oral GLP-1 achieved a 1.7% placebo-adjusted HbA1c reduction at week 12 in a Phase II diabetes trial, while ASC37's half-life is six-fold longer than retatrutide, offering a counterpoint.
News
PUBT · Ascletis Oral Obesity Drug Combination Shows 10.5% Weight Loss in Monkey Study
Market Movers · Ascletis drops 6%
PUBT · Ascletis Submits FDA IND Application for ASC30_39 Obesity Treatment
Market Movers · Ascletis climbs 7%
Weekly Review · Weekly Recap | ASCLETIS-B -4.31%, ObesityWeek data in focus
PUBT · Ascletis Pharma Files HKEX Next-Day Disclosure Return on Share Buyback
